← back to search

David Gallinson

Summit Medical Group (United States) · US
Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Cholangiocarcinoma and Gallbladder Cancer Studies, and Fibroblast Growth Factor Research.
h-index
8
citations
1,826
works
20
NIH funding
primary concept
Medicine
email

Recent publications

A randomized phase 2 study of an individualized neoantigen-targeting immunotherapy in patients with newly diagnosed metastatic microsatellite stable colorectal cancer (MSS-CRC).
Journal of Clinical Oncology 2025cited by 10position: middledoi
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202
ESMO Open 2024cited by 73position: middledoi
O-2 Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202
Annals of Oncology 2022cited by 19position: middledoi
Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.
Journal of Clinical Oncology 2021cited by 25position: middledoi
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
The Lancet Oncology 2020cited by 1,557position: middledoi
FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
Annals of Oncology 2019cited by 59position: middledoi
Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer
Clinical Colorectal Cancer 2013cited by 34position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Adrian Murphy · Johns Hopkins Medicine5 papers (2019–2024)Hui‐Ling Zhen · Huawei Technologies (Sweden)5 papers (2019–2024)Gina M. Vaccaro · Tennessee Oncology5 papers (2019–2024)Davide Melisi · State Healthcare Institution "Regional Clinical Oncological Dispensary"5 papers (2019–2024)Christine Lihou · Incyte (United States)5 papers (2019–2024)Efrat Dotan · Diakonessenhuis hospital5 papers (2019–2024)Daniel V.T. Catenacci · University of Chicago5 papers (2019–2024)Antoine Hollebecque · Institut Gustave Roussy5 papers (2019–2024)Andrew Scott Paulson · Texas Oncology4 papers (2019–2024)Mitesh J. Borad · Mayo Clinic4 papers (2019–2024)Raed Moh’d Taiseer Al-Rajabi · The University of Kansas Cancer Center4 papers (2019–2022)Do‐Youn Oh · New Generation University College4 papers (2019–2024)Vaibhav Sahai · University of Illinois Urbana-Champaign4 papers (2019–2024)Arndt Vogel · Federal Institute for Risk Assessment4 papers (2019–2024)Ghassan K. Abou‐Alfa · Verizon (United States)4 papers (2019–2022)Luis Féliz · Incyte (United States)3 papers (2019–2021)Eric Van Cutsem · KU Leuven3 papers (2019–2021)E. Van Cutsem · Universitair Ziekenhuis Leuven2 papers (2022–2024)Peter Vogel · Ducks Unlimited1 papers (2022–2022)Anthony V. Nguyen · Indiana University School of Medicine1 papers (2025–2025)